Exchange: NASDAQ·Updated 07:30 PM EST
VERU logo

VERU Veru Inc

$1.93
$0.17
(8.06%)
Today
Closed $1.94
$0.01
(0.52%)
After Hours
EarningsDec 17
Mkt Cap$35.98M
Vol247,922.00

About VERU

Veru, Inc. is a late clinical stage biopharmaceutical company focused on developing novel medicines and treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. The company was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1971 and is headquartered in Miami, FL.
43

Bearish Sentiment

How do you feel about VERU?

mrkymrk
$VERU nice volume. Praying for the day this gets some real clarity and investors behind it.
8
cray1965
$VERU Veru Obesity week abstract: Enobosarm in Patients With Obesity on Semaglutide: Quality Weight Loss & Better Physical Function. Results: In subjects ≥65 years of age, semaglutide alone (P+S) resulted in 50% (15/30) experiencing ≥10% reduction in stair climb power and even though the subjects lost weight, 41% (12/29) had an increase in the time (got slower) to go up the stairs. While Enobsarm + Sema (E3+S) (n=29) showed an increase in stair climb power (SCP)(+16.48% placebo corrected) and a decrease (got faster) in stair climb time (SCT)(-16.31% placebo corrected) compared to P+S (n=30) at 16 weeks. The weight loss was on average 68% fat (32% lean mass) in the P+S group and 100% fat (0% lean mass) in the E3+S group. ' In short, the >65>35 BMI cohort(Plateau population) showed more relative fat loss and more physical function improvement than the general Quality population(>60>30 BMI.
7
mrkymrk
$VERU once Semaglutide goes generic in 2031, It is VERU that holds all the cards in relation to the potential combo therapy. Hmmm…I never thought of it this way but that gives VERU A LOT more leverage in negotiations. Of course they need cash, so there’s that. But at least the default is in VErU’s favor. Protected Market Niche: If clinical trials succeed and the FDA approves the combination, Veru would hold exclusive rights to market and sell the specific dual-therapy regimen (or co-formulated product) into the mid-2040s, insulating that specific "muscle-sparing" treatment approach from generic competition.
6
Eesnimi
$VERU From 240 to 2. Veru has had 99% loss of stock price. Normality starts at 50+ . There is +2500% needed to arrive there. Price target 24 is very low it is s only 2.4 before the reverse split. Under 10 this scam company should not even be allowed to trade
5
mrkymrk
$VERU $.20 split adjusted. What do I do with all this shareholder value, Mitch?!?!? Please give yourselves end of year bonuses and more shares. You all deserve it for all the shareholder value you have created over 10 years of doing nothing but wasting our money to enrich yourselves.
5
cray1965
$VERU Also, for Lilly, double the weight loss probably means double the muscle loss, but yeah I'm not sure what they could acquire to solve that either.
5
GenralZod
$VERU more bad NVO news with retatrutide. Nice! so, NVO really needs something. wonder what they could develop or acquire to turn the tide.
1
1
cray1965
$VERU Novo’s CEO told Fierce that the company remains on the hunt for deals that “close some of the gaps” in its pipeline....When asked by Fierce this morning whether he agreed with reporting that investors had been underwhelmed by the company’s deal-making strategy, Doustdar said Novo was still on the hunt for acquisitions. “We continue, of course, to mention that we are looking and searching across all of our therapy areas for innovation that fits and closes, maybe, some of the gaps that we have, as well as, of course, synergizes with what we're doing ourselves,” the CEO responded. “We remain disciplined,” Doustdar continued. “I think, for us, it’s not about running and making sure we close a certain number of deals just to satisfy the headline news.” “For us, it really starts [by] mak[ing] sure that we deeply search into what is strategically fitting into our portfolio of products and our strategy, and we'll continue doing that.”
3
Rayvio_News_Filter
$VERU 🏥 Veru Inc. presented new post hoc Phase 2b QUALITY results showing that in patients aged 65 and older receiving semaglutide, adding enobosarm preserved lean mass and stair-climb function at 16 weeks versus declines with placebo. Actionable market event
2
gogogomm
$VERU Ketamine-free, one of the NRXP drugs, has received FDA approval. However, the stock price is moving in the opposite direction. Today is the opportunity. lets go to the moon fda approved $NRXP omg
2
BluntForceOptions
$VERU ICYMI: Ahead of next week's ObesityWeek 2026 conference (Nov 14–17 in D.C.), Veru confirmed CSO Dr. Gary Barnette will deliver an oral podium presentation on Mon, Nov 16 at 5:15 PM EST. They're presenting new post-hoc physical function results for enobosarm in older patients (≥65) on GLP-1 therapy from the positive Phase 2b QUALITY study. With the Phase 2b PLATEAU trial fully enrolled (239 patients) and interim data on deck for Q1 2027, Monday's readout is a key scientific spotlight on the muscle-preservation thesis. Worth keeping on the radar heading into Monday's close.

Advertisement|Remove ads.